Foresight LabsA jacket, two journeys

European Union

EU Declines To Renew Medetomidine Approval For Antifouling Products

The EU will not renew medetomidine approval for antifouling biocides. A separate restriction on treated articles applies from 8 June 2027.

Foresight

2 min readAI-drafted, expert reviewed

Painted lower hull of a vessel raised on blocks in a boatyard

The European Commission has decided not to renew medetomidine's approval for antifouling biocides under product-type 21. Implementing Decision (EU) 2026/2567, adopted on 19 November and published on 20 November 2026, enters into force on 10 December 2026.

The decision also sets a market deadline for articles treated with, or intentionally incorporating, medetomidine for this use. They may no longer be placed on the EU market from 8 June 2027.

Reasons For Non-Renewal

The decision's assessment cites the European Chemicals Agency's May 2024 opinion identifying endocrine-disrupting properties affecting humans and non-target organisms. The assessment could not establish a safe exposure level for those properties or conclude that the representative product's risks were acceptable.

The Commission concluded that the renewal conditions were not met. It also found that none of the conditions allowing approval despite an exclusion criterion had been satisfied. These findings concern the substance's use in antifouling biocides.

Alternatives And Earlier Extensions

The decision identifies four chemical alternatives considered suitable and sufficient for commercial and recreational vessels: DCOIT, copper thiocyanate, cuprous oxide and tralopyril. Member State representatives could not reach the same conclusion for the identified non-chemical alternatives because of availability or technical limitations.

Medetomidine was originally approved for product-type 21 in 2015. Its expiry date was subsequently postponed while the renewal application was assessed. A companion decision, (EU) 2026/2566, repeals the latest extension, which had set expiry at 31 December 2026. That repeal also takes effect on 10 December 2026.

Questions about this change

When Does The EU Restriction On Medetomidine-Treated Antifouling Articles Apply?

From 8 June 2027, articles treated with or intentionally incorporating medetomidine for biocidal product-type 21 use may no longer be placed on the EU market. The non-renewal decision enters into force on 10 December 2026.

Does The EU Medetomidine Decision Cover All Uses Of The Substance?

No. Decision (EU) 2026/2567 concerns approval for biocidal product-type 21, which covers antifouling products, and articles treated for that use. It does not establish a ban on every use of medetomidine.

Join 3,500+ professionals staying ahead

Foresight Weekly brings the week's regulatory changes across chemicals, product safety, sustainability, ESG and EHS into one email.

Free. Unsubscribe at any time.

Read by professionals at

  • Boeing
  • AstraZeneca
  • Siemens
  • PepsiCo
  • SpaceX